Inhibition of fibrinolysis by lipoprotein(a)

Annals of the New York Academy of Sciences

Volumn 936, Issue , 2001, Pages 261-275

  Anglés Cano, Eduardo ^a   De La Díaz, Aurora Peña ^b   Loyau, Stéphane ^a  

^a INSERM   (France)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Atherosclerosis; Atherothrombosis; Fibrin surface; Fibrinogen; Fibrinolysis; Kringle domains; Lysine binding site; Macrophages; Monocytes; Plasmin; Plasminogen; Plasminogen activation; Plasminogen activator inhibitor; Thrombosis; Tissue plasminogen activator; Urokinase

Indexed keywords

APOLIPOPROTEIN B; FIBRIN; LIPOPROTEIN A; LYSINE; PLASMIN;

AMINO ACID SUBSTITUTION; BINDING AFFINITY; BINDING SITE; CARDIOVASCULAR RISK; CHEMICAL BINDING; CONFERENCE PAPER; FIBRIN METABOLISM; FIBRINOLYSIS; HUMAN; KRINGLE DOMAIN; MACROPHAGE; MONOCYTE; PHENOTYPE; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; RISK FACTOR;

EID: 0034969089     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03514.x     Document Type: Conference Paper

References (68)

1. A new serum type system in man - The Lp system
2. Partial amino acid sequence of apolipoprotein(a) shows that is homologous to plasminogen
3. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
4. Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis
5. Lp(a) Lipoprotein in cardiovascular disease
6. The mysteries of lipoprotein(a)
7. Lipoprotein (a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men
8. Lipoprotein(a) and coronary heart disease risk. A nested case-control study of the Helsinki Heart Study participants
9. A prospective study of lipoprotein (a) and the risk of myocardial infarction
10. Epidemiology of Lp(a) lipoprotein: Its role in atherosclerotic/thrombotic disease
11. Does lipoprotein(a) (Lp(a)) compete with plasminogen in human atherosclerotic lesions and thrombi?
12. Multiple binding with identical linkage: A mechanism that explains the effect of lipoprotein(a) on fibrinolysis
13. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin
14. Kringles: Modules specialized for protein binding
15. The fibrin-binding site of human plasminogen
16. The refined structure of the e-aminocaproic acid complex of human plasminogen kringle 4
17. Characterization of the binding of plasminogen to fibrin surfaces: The role of carboxy-terminal lysines
18. A structural assessment of the apo(a) protein of human lipoprotein(a)
19. Physicochemical properties of apolipoprotein(a) and Lp(a) derived from the dissociation of human plasma Lp(a)
20. 4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly
21. Comparison of ligand-binding sites of modeled Apo(a) kringle-like sequences in Human lipoprotein(a)
22. The structures of domains of blood proteins
23. Structure of the ω-aminocarboxylic acid-binding sites of human plasminogen
24. Amino acids of the recombinant kringle 1 domain of human plasminogen that stabilize its interaction with ω-amino acids
25. Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands e-aminocaproic acid and trans4-(aminomethyl)cyclohexane-l-carboxilic acid
26. The structure of recombinant plasminogen kringle 1 and the fibrin binding site
27. Proton magnetic resonance study of lysine-binding to the kringle 4 domain of human plasminogen. The structure of the binding site
28. Recombinant kringle IV-10 modules of human apolipoprotein(a): Structure, ligand binding modes, and biological relevance
29. Proteolytic processing and physiological regulation
30. Mapping the active site of papain with the aid of peptide substrates and inhibitors
31. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin
32. Elimination of the Cys558-Cys566 bond in Lys78-plasminogen - Effect on activation and fibrin interaction
33. Expression of recombinant human plasminogen in mammalian cells is augmented by suppression of plasmin activity
34. Effect of plasminogen activators on human recombinant apolipoprotein(a) having the plasminogen activation cleavage site
35. Distinct mechanisms contribute to stringent substrate specifity of tissue-type plasminogen activator
36. A potential basis for the thrombotic risks associated with lipoprotein(a)
37. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis
38. Kinetics of the activation of plasminogen by human tissue plasminogen activator
39. Initial plasmin-degradation of fibrin as the basis of a positive feedback mechanism in fibrinolysis
40. Location of plasminogen - Binding sites in human fibrin (ogen)
41. The plasma carboxypeptidases and the regulation
42. Effects of kringles derived from human plasminogen on fibrinolysis in vitro
43. Lipoprotein(a), fibrin binding, and plasminogen activation
44. Lipoprotein (a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator
45. Interaction of Lp(a) with plasminogen binding sites on cells
46. Fibrin, lipoprotein(a), plasmin interactions: A model linking thrombosis and atherogenesis
47. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator
48. Apolipoprotein(a) and plasminogen interactions with fibrin: A study with recombinant apolipoprotein(a) and isolated plasminogen fragments
49. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation
50. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells
51. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells
52. Lipoprotein(a) inhibits the generation of transforming growth factor b: An endogenous inhibitor of smooth muscle cell migration
53. Activation of transforming growth factor is inhibited in transgenic apolipoprotein(a) mice
54. Occlusive arterial thrombosis in cynomologous monkeys with varying plasma concentrations of lipoprotein(a)
55. Apolipoprotein(a) attenuates endogenous fibrinolysis in vivo in a rabbit jugular vein thrombosis model
56. Antifibrinolytic acitivity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant for tissue plasminogen activator-mediated thrombolysis
57. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice
58. Changes of genetic apolipoprotein phenotypes caused by liver transplantation
59. Lipoprotein(a) in Renal Disease
60. Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin - A study with individual plasmas presenting natural variations of Lp(a)
61. Effect of individual plasma lipoprotein(A) variations in vivo on its competition with plasminogen for fibrin and cell binding - An in vitro study using plasma from children with idiopathic nephrotic syndrome
62. Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for non common "null" allele at the apo(a) locus
63. Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentations in plasma
64. Significant association between low molecular weight apolipoprotein (a) isoforms and intermittent claudication
65. Relation of serum lipoprotein(a) and apolipoprotein(a) pheno to coronary heart disease in patients with familial hypercholesterolemia
66. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations
67. Does apolipoprotein (a) heterogeneity influence lipoprotein (a) effects on fibrinolysis?
68. Role of lipoprotein(A) and apolipoprotein(A) phenotype in atherogenesis - Prospective results from the Bruneck study